NYSE:PFE

Pfizer - PFE Stock Forecast, Price & News

$44.34

+0.37 (+0.84%)

(As of 02/2/2023 12:00 AM ET)

Add

Compare

Today's Range: $43.50
▼
$44.46
50-Day Range: $43.55
▼
$54.48
52-Week Range: $41.44
▼
$56.32

Volume: 35.16 million shs
Average Volume: 26.47 million shs
Market Capitalization: $248.89 billion

P/E Ratio: 8.09
Dividend Yield: 3.71%
Price Target: $52.13

Institutional Ownership

Pfizer MarketRank™ Forecast

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 17.6% Upside
$52.13 Price Target
Short Interest: Healthy
0.66% of Shares Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -1.95
Upright™ Environmental Score
News Sentiment: 0.06
Based on 53 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 27.46%
From $3.35 to $4.27 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.47 out of 5 stars

Medical Sector

1st out of 1,030 stocks

Pharmaceutical Preparations Industry

1st out of 502 stocks

3.2

Analyst's Opinion

Consensus Rating
Pfizer has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 4 buy ratings, 8 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $52.13, Pfizer has a forecasted upside of 17.6% from its current price of $44.34.
Amount of Analyst Coverage
Pfizer has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

5.0

Short Interest

Percentage of Shares Shorted
0.66% of the outstanding shares of Pfizer have been sold short.
Short Interest Ratio / Days to Cover
Pfizer has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Pfizer has recently decreased by 12.60%, indicating that investor sentiment is improving significantly.

5.0

Dividend Strength

Dividend Leadership
Pfizer is a leading dividend payer. It pays a dividend yield of 3.71%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Pfizer has been increasing its dividend for 12 years.
Dividend Coverage
The dividend payout ratio of Pfizer is 29.93%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Pfizer will have a dividend payout ratio of 38.41% next year. This indicates that Pfizer will be able to sustain or increase its dividend.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Pfizer has received a 68.15% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Covid-19 vaccines", "Apixaban", and "Pneumococcal vaccines" products. See details.
Environmental Sustainability
The Environmental Impact score for Pfizer is -1.95.

2.8

News and Social Media Coverage

News Sentiment
Pfizer has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 53 news articles for Pfizer this week, compared to 21 articles on an average week.
Social Mentions This Week
MarketBeat has tracked 1 reddit mention for Pfizer this week, compared to 6 mentions on an average week.
Search Interest
303 people have searched for PFE on MarketBeat in the last 30 days. This is an increase of 52% compared to the previous 30 days.
MarketBeat Follows
95 people have added Pfizer to their MarketBeat watchlist in the last 30 days. This is an increase of 22% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Pfizer insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.05% of the stock of Pfizer is held by insiders.
Percentage Held by Institutions
67.62% of the stock of Pfizer is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Pfizer are expected to grow by 27.46% in the coming year, from $3.35 to $4.27 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Pfizer is 8.09, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.23.
Price to Earnings Ratio vs. Sector
The P/E ratio of Pfizer is 8.09, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 162.22.
Price to Earnings Growth Ratio
Pfizer has a PEG Ratio of 1.46. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Pfizer has a P/B Ratio of 3.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Pfizer (NYSE:PFE) Stock

Pfizer Inc. is a US-based multinational biotech company. The company operates as a research-based pharmaceutical company focused on the discovery, production and marketing of medicines and vaccines. It is the 2nd largest drugmaker globally by revenue and is ranked 64th on the Fortune 500 list. The company’s avenues of research include Immunology, Oncology, Cardiology, Endocrinology and Neurology.

Regarding its product line, the company has at least ten blockbuster drugs producing more than $1 billion in avenue revenue each. The company brought in over $81 billion in total revenue in 2021. The US is its main market and represents roughly 50% of all revenue. China and Japan make up roughly 12% of the business, while the rest come from the “rest of the world”. It employs roughly 79,000 people and is headquartered in New York state.

Pfizer Inc. was founded in 1849 by Charles Pfizer Sr. and his cousin Charles Earhart. The two were German immigrants and chemists that set up shops outside New York City to make medicinal compounds. The first major success was an antiparasitic called santonin, and the commercialization of citric acid-making technologies quickly followed that up. Their success with citric acid led to the company’s expansion and other major discoveries.

World War I caused a shortage of materials for making citric acid and forced the company to seek alternatives. The one they latched on to was the fermentation of certain fungi known to produce citric acid naturally. This led to the advancement of fermentation technology that was later used in the commercial production of penicillin and then the advancement of antibiotics in general.

Pfizer Inc was incorporated on June 2nd, 1942 in Delaware, and another period of expansion began. The postwar drop in demand for penicillin led to the discovery of newer, more marketable antibiotics and cemented the company’s role in modern medicine. By the time he 80s rolled around, the company was trading on the New York Stock Exchange and on the path to developing today’s blockbuster lineup.

The company’s top seller in 2021 was Comirnaty, a COVID-19 vaccine. It generated nearly $37 billion in 2021 and was followed by Prevnar, Ibrance and Eliquis with just over $5 billion in sales each. Other blockbuster names on Pfizer’s list include Xeljanz and Enbrel, each bringing in $3.5 billion. Pfizer operates 39 research and production facilities worldwide and sells its products in 125 countries.

As of 2022, the company had a robust pipeline of potential treatments, with more than 220 in some stage of clinical trials. Among its leading candidates is a vaccine for RSV, a life-threatening respiratory disease affecting children. 2021 highlights include 8 FDA approvals, four new regulatory submissions and 13 new trial startups. Pfizer is also a well-known dividend payer and has returned more than $8.7 billion to shareholders since going public.

Receive PFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.

PFE Stock News Headlines

February 2, 2023 | marketbeat.com

Cathie Woods' Ark Innovation ETF Set To Rebound in 2023? (PFE)

Can gains in Tesla, Zoom, Exact Sciences, and other growth stocks set the stage for Cathie Woods' Ark Innovation Fund to stage a comeback in 2023?

February 1, 2023 | marketbeat.com

Novavax Shares Jumped in January While Others Slipped (PFE)

Updated FDA Covid vaccine policy could've boosted NVAX shares at the end of January, when other pharma stocks slipped, but it may not affect the bottom line.

February 2, 2023 | Investor Place Media (Ad)

Cash Holders STILL Aren't Taking Steps to Prepare

Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.

February 1, 2023 | marketbeat.com

Pfizer Stock: What the Bulls and Bears are Getting Wrong

Pfizer stock is bouncing up and down after mixed Q4 earnings. There's been an emotional battle between bulls and bears but it's time for both to get rational

January 31, 2023 | marketbeat.com

Drugmaker Pfizer starts low with 2023 earnings forecast

Pfizer surprised Wall Street on Tuesday by predicting bigger-than-expected sales drops this year for two key products: its COVID-19 vaccine and treatment

January 31, 2023 | marketbeat.com

Pfizer tops 4Q expectations, starts low with 2023 forecast

COVID-19 vaccine booster shots and treatments for the virus helped push Pfizer to a better-than-expected final quarter of 2022

January 30, 2023 | dividendstocks.com

AbbVie Stock: Dividend King ABBV Overview (PFE)

January 28, 2023 | marketbeat.com

MarketBeat Week in Review – 1/23- 1/27 (PFE)

Markets were pushing hard to continue the rally as.recession fears and layoff announcements offset two data points that suggest inflation may be easing

February 2, 2023 | Investor Place Media (Ad)

Cash Holders STILL Aren't Taking Steps to Prepare

January 26, 2023 | marketbeat.com

How Could GSK's RSV Vaccine Change its Valuation? (PFE)

GSK's RSV vaccine could be a good earner for the company, according to outside analysts and its own predictions for the future.

January 25, 2023 | marketbeat.com

Is the Pain Over for Baudax Bio Investors after a 70% Spike? (PFE)

Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000.

January 23, 2023 | marketbeat.com

When Does Pfizer Become A Bargain? (PFE)

With a price-to-earnings ratio of less than 9 and a dividend yield of 3.63% you have to be thinking that Pfizer may a bit of a bargain down here.

February 2, 2023 | finance.yahoo.com

Bristol-Myers (BMY) Q4 Earnings Top, Revlimid Generic Impact Sales

February 2, 2023 | finance.yahoo.com

COVID is 'pretty much out of the models' for pharma companies: Wells Fargo analyst